Низкий уровень адипонектина в крови как фактор риска тяжелого течения ишемической болезни сердца

E. A. Polyakova

doi:10.34687/2219-8202.JAD.2022.01.0005

Authors

E. A. Polyakova First Saint-Petersburg State Pavlov Medical University

DOI:

https://doi.org/10.34687/2219-8202.JAD.2022.01.0005

Abstract

Objective. To study the role and prognostic significance of various concentrations of total (TA) and high molecular weight (HMWA) adiponectin in blood serum in severe coronary heart disease (CHD).

Methods. The study included 427 people: the main group - 343 examined with an CHD and the comparison group without CHD - 84 people who underwent examination of the cardiovascular system for other reasons not related to CHD. All patients with CHD, as well as those examined without CHD, underwent selective coronary angiography (strictly according to indications). The concentration of TA and HMWA was measured by the ELISA method. Statistical data analysis was performed using the statistical software package SPSS, version 17.0 (SPSS Inc., USA).

Results. The concentration of TA and HMWA was significantly lower in patients with CHD than in those examined from the comparison group without CHD. The concentration of TA in men was significantly lower than in women, regardless of the presence of CHD. The content of HMWA in the blood serum of men with CHD with stenosis of 3 or more coronary arteries was significantly lower than in patients with stenosis of 1–2 coronary arteries. The concentration of HMWA in men and women with stenosis of 1–2 coronary arteries did not differ, but among patients CHD with stenosis of 3 or more coronary arteries was significantly lower in men than in women. The risk of developing endpoints (EP) in men with CHD depends on the concentration of HMWA in the blood serum, and when its concentration is less than 1.1 μg/ml, the risk of their development is increased by 7.1 times. Prospective analysis (average 41 months) showed that in patients with CHD with registered EP, the concentration of TA and HMWA in the blood serum was significantly lower than in patients with CHD without EP.

Conclusions. A decrease in the concentration of adiponectin in the blood is associated with a more severe course of CHD, especially in male patients. The concentration of HMWA in the blood serum of less than 1.1 μg/ml leads to an increase in the risk of developing the endpoint in men with CHD by 7.1 times. The onset of endpoints in CHD patients is associated with a significantly lower serum adiponectin concentration.

Downloads

Download data is not yet available.

References

Zhao S, Kusminski CM, Scherer PE. Adiponectin, Leptin and Cardiovascular Disorders. Circ Res. 2021;Jan 8;128(1):136-149.

Polyakova EA, Berkovich OA, Baranova EI. Prognostic Value of Epicardial fat ftickness in Coronary Heart Disease Patients After Myocardial Revascularization. Kardiologiia. 2020;60(3):4–13. (Russian: Полякова Е. А., Беркович О. А., Баранова Е. И. Прогностическое значение толщины эпикарди- альной жировой ткани у больных ишемической болезнью сердца, перенесших реваскуляризацию миокарда. Кардиология. 2020;60(3):4–13.)

Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, Seidell J, Magni P, Santos RD, Arsenault B, Cuevas A, Hu FB, Griffin B, Zambon A, Barter P, Fruchart JC, Eckel RH; International Atherosclerosis Society; International Chair on Cardiometabolic Risk Working Group on Visceral Obesity. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;Sep;7(9):715-725.

Polyakova EA, Nifontov SE, Butomo MI, Berkovich OA, Baranova EI. Echocardiographic assessment of the epicardial fat layer in patients with various stages of coronary artery disease. The Journal of Atherosclerosis and Dyslipidemias. 2019;4(37):54-63. (Russian: Полякова Е.А., Нифонтов С.Е., Бутомо М.И., Беркович О.А., Е.И. Баранова. Возможности ультразвукового метода исследования эпикардиальной жировой ткани у пациентов с ишемической болезнью сердца при различной тяжести поражения коронарных артерий. Атеросклероз и дислипидемии. 2019;4(37):54-63.)

Salazar J, Luzardo E, Mejías JC, Rojas J, Ferreira A, Rivas-Ríos JR, Bermúdez V. Epicardial Fat: Physiological, Pathological, and Therapeutic Implications. Cardiol Res Pract. 2016;2016:1291537.

Ramakrishnan N, Auger K, Jialal I. Biochemistry, Adiponectin. 2021 May 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2021;Jan–. PMID: 30725726

Bottner A, Kratzsch J, Muller G, Kapellen TM, Bluher S, Keller E, Bluher M, Kiess W. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab. 2004;89:4053-4061.

Su SC, Chiang CF, Hsieh CH, Lu GH, Liu JS, Shieh YS, Hung YJ, Lee CH. Growth arrest-specific 6 modulates adiponectin expression and insulin resistance in adipose tissue. J Diabetes Investig. 2021;Apr;12(4):485-492.

Shirazi FKH, Khodamoradi Z, Jeddi M. Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with Polycystic Ovarian Syndrome (PCOS). BMC Endocr Disord. 2021;Mar 9;21(1):45.

Zhao S, Kusminski CM, Scherer PE. Adiponectin, Leptin and Cardiovascular Disorders. Circ Res. 2021;Jan 8;128(1):136-149.

Cote M, Cartier A, Reuwer AQ, Arsenault BJ, Lemieux I, Despres JP, Wareham NJ, Kastelein JJ, Boekholdt SM, Khaw KT. Adiponectin and risk of coronary heart disease in apparently healthy men and women (from the EPIC-Norfolk Prospective Population Study). Am J Cardiol. 2011;108: 367-373.

Refaat H, Tantawy A. Low Plasma Adiponectin Levels Are Associated With Vulnerable Plaque Features in Patients With Acute Coronary Syndrome: An Optical Coherence Tomography Study. Cardiovasc Revasc Med. 2021;Apr;25:63-71.

Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291: 1730-1737.

Sook Lee E, Park SS, Kim E, Sook Yoon Y, Ahn HY, Park CY, Ho Yun Y, Woo Oh S. Association between adiponectin levels and coronary heart disease and mortality: a systematic review and meta-analysis. Int J Epidemiol. 2013;Aug;42(4):1029-39.

Jensen MK, Bertoia ML, Cahill LE, Agarwal I, Rimm EB, Mukamal KJ. Novel metabolic biomarkers of cardiovascular disease. Nat Rev Endocrinol. 2014;10: 659-672.

Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, Danesh J, Whincup PH. Adiponectin and coronary heart disease: A prospective study and meta-analysis. Circulation. 2006;114: 623-629.

Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem. 2003;278: 2461–2468.

Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, et al. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23: 85–89.

Koenig W, Khuseyinova N, Baumert J, Meisinger C, Lowel H. Serum concentrations of adiponectin and risk of type 2 diabetes mellitus and coronary heart disease in apparently healthy middle-aged men: results from the 18-year follow-up of a large cohort from southern Germany. J Am Coll Cardiol. 2006;48: 1369–1377.

Wolk R, Berger P, Lennon RJ, Brilakis ES, Davison DE, et al. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J. 2007;28: 292–298.

Maahs DM, Ogden LG, Kinney GL, Wadwa P, Snell-Bergeon JK, et al. Low plasma adiponectin levels predict progression of coronary artery calcification. Circulation. 2005;111: 747–753.

von Eynatten M, Schneider JG, Humpert PM, Kreuzer J, Kuecherer H, et al. Serum adiponectin levels are an independent predictor of the extent of coronary artery disease in men. J Am Coll Cardiol. 2006;47: 2124–2126.

Otsuka F, Sugiyama S, Kojima S, Maruyoshi H, Funahashi T, et al. Plasma adiponectin levels are associated with coronary lesion complexity in men with coronary artery disease. J Am Coll Cardiol. 2006;48: 1155–1162.

Selcuk MT, Selcuk H, Temizhan A, Maden O, Saydam GS, et al. Impact of plasma adiponectin levels to the presence and severity of coronary artery disease in patients with metabolic syndrome. Coron Artery Dis. 2008;19: 79–84.

Rahmani A, Toloueitabar Y, Mohsenzadeh Y, Hemmati R, Sayehmiri K, Asadollahi K. Association between plasma leptin/adiponectin ratios with the extent and severity of coronary artery disease. BMC Cardiovasc Disord. 2020;Nov 4;20(1):474.

Gan L, Yang L, Yan G. Predict value of adiponectin for coronary atherosclerosis plaques according to computed tomography angiography in an asymptomatic population. Clin Imaging. 2018;Sep-Oct;51:174-179.

Kojima S, Funahashi T, Sakamoto T, et al. The variation of plasma concentrations of a novel, adipocyte derived protein, adiponectin, in patients with acute myocardial infarction. Heart. 2003;89:667.